Safety and efficacy of zoledronic acid

Zoledronic Acid Injection (Zoledronic Acid) is a bisphosphonate drug developed by Novartis. It is a third-generation bisphosphonate. Compared with the first and second generations, it has the clinical advantages of stronger anti-bone resorption and reducing the incidence of bone-related events. It is currently the only bisphosphonate drug approved in the world for different types of bone metastases from solid tumors and bone damage in multiple myeloma.

In 2001, Zoledronic Acid injection (Zoledronic Acid) was first approved in the European Union and subsequently approved for marketing in the United States, Japan and other countries. It is used to treat hypercalcemia caused by malignant tumors, and is used in combination with standard anti-tumor drugs to treat bone damage in patients with solid tumor bone metastases and multiple myeloma patients.

How safe and effective is zoledronic acid?

The purpose of the clinical trial is to observe the clinical efficacy and safety of Zoledronic Acid in the treatment of primary osteoporosis. Methods Zoledronic acid injection was used to treat 35 patients with primary osteoporosis aged 57 to 85 years old. The relief of bone pain, changes in blood calcium, phosphorus, alkaline phosphatase, osteocalcin, and urinary DPD/Cr were observed before and after treatment. Dual-energy X-ray absorptiometry was used to measure the patient's bone density before and after treatment. Observe the occurrence of adverse reactions in patients after treatment. Results: All patients' bone pain symptoms were significantly improved, and the overall excellent and good rate reached 100%. There were no significant changes in serum calcium, phosphorus, alkaline phosphatase, and osteocalcin, and urine DPD/Cr was significantly lower than before treatment (P<0.01). The density increased significantly compared with before treatment (P<0.01), and no obvious adverse reactions occurred in 35 patients. Conclusion (Zoledronic Acid) is a safe and effective drug for the treatment of primary osteoporosis.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: